← All trials
NCT05169008
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 25, 2022
- Primary completion
- May 25, 2023
- Completion date
- Aug 25, 2023
- First posted
- Dec 23, 2021
- Last posted
- Sep 7, 2022
- Enrollment
- 1000
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tianjin Cansino Biotechnology IncLead sponsor
- University of ChileOverall official - principal investigator
- Beijing Institute of BiotechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.